5-Amino-1MQ
An experimental fat-loss compound. An NNMT inhibitor that targets the enzyme driving metabolic stagnation in obesity, with animal and in-vitro data only and no published human results.
5-Amino-1MQ: An experimental fat-loss compound. An NNMT inhibitor that targets the enzyme driving metabolic stagnation in obesity, with animal and in-vitro data only and no published human results. 5-Amino-1MQ blocks an enzyme called NNMT that gets overactive in obesity and stalls fat loss.
5-Amino-1MQ blocks an enzyme called NNMT that gets overactive in obesity and stalls fat loss. Oral capsule. Early human data is promising but limited, best treated as a metabolic adjunct, not a hero.
Who it's for
- →Users in a stalled cut
- →Plateau-broken stacks late in a diet phase
- →People with sluggish metabolic markers
What to expect
- Week 1
Subtle. Some users report energy bump.
- Week 4
Body comp shifts in stacked-with-diet users.
- Week 8
Plateau. Cycle off.
Looking at 5-Amino-1MQ? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for 5-Amino-1MQ.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Selective inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in obese adipose tissue. NNMT inhibition restores cellular methylation balance and unblocks fat metabolism.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠No long term human safety data, short cycles only
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • Liver enzymes baseline + week 8 (limited data, monitor)
Common mistakes
- • Treating it as a primary fat-loss agent rather than a metabolic adjunct
- • Running long cycles without the safety data to back it
- • Expecting GLP-class results
Community patterns
New to 5-Amino-1MQ? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if 5-Amino-1MQ changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about 5-Amino-1MQ or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is 5-Amino-1MQ?+
Is 5-Amino-1MQ FDA approved?+
Is 5-Amino-1MQ legal?+
Is 5-Amino-1MQ banned by WADA?+
Are you still natty after taking 5-Amino-1MQ?+
Do doctors prescribe 5-Amino-1MQ?+
What's the typical dose of 5-Amino-1MQ?+
What are the side effects of 5-Amino-1MQ?+
How long until 5-Amino-1MQ starts working?+
What can you stack with 5-Amino-1MQ?+
Where do people get 5-Amino-1MQ?+
5-Amino-1MQ vs MOTS-c, which is better?+
Head-to-head with 5-Amino-1MQ
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.